These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8071132)

  • 1. Combination effect of clindamycin with ceftazidime and cefoperazone in inducing filamentous growth of Enterobacter cloacae and Pseudomonas aeruginosa.
    Nishihata T; Kunieda S; Mikawa M; Nakahama C; Soejima R
    J Antibiot (Tokyo); 1994 Jul; 47(7):843-7. PubMed ID: 8071132
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
    Kalman D; Barriere SL; Johnson BL
    Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of clindamycin on production of beta-lactamase in beta-lactam-resistant bacteria.
    Nishihata T; Kunieda S; Nakahama C; Soejima R
    Biol Pharm Bull; 1994 May; 17(5):715-20. PubMed ID: 7920440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial activity of a novel aminothiazolylglycylcephalosporin, MT0703S, compared with that of ceftazidime, cefoperazone and aztreonam.
    Okamoto R; Hara T; Yoshida T; Orikasa Y; Ogino H; Iwamatsu K; Inouye S
    Drugs Exp Clin Res; 1990; 16(4):157-65. PubMed ID: 2127567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cefoxitin and clindamycin on selection of derepressed mutants in Enterobacter cloacae.
    Saverino D; Milintenda-Floriani F; Medeiros AA
    New Microbiol; 2004 Jul; 27(3):249-53. PubMed ID: 15460527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.
    Turcotte A; Simard M; Morin NJ; Beauchamp D; Bergeron MG
    Antimicrob Agents Chemother; 1997 Feb; 41(2):401-9. PubMed ID: 9021198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro antimicrobial studies with the combination of cefoperazone and sulbactam.
    Greenberg RN; Baker M; Meade DW; Chang Y; Danko LS
    J Antimicrob Chemother; 1993 Dec; 32(6):912-3. PubMed ID: 8144438
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of isepamicin against Pseudomomas aeruginosa and Enterobacter cloacae strains resistant to amikacin: a preliminary report.
    Giamarellou H; Pephanis A; Florentin I; Petrikkos G; Avlamis A; Grammatikou M
    J Chemother; 1989 Jul; 1(4 Suppl):399-400. PubMed ID: 16312458
    [No Abstract]   [Full Text] [Related]  

  • 9. Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae.
    Chan WC; Li RC; Ling JM; Cheng AF; Schentag JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):55-60. PubMed ID: 10381101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity.
    Hiruma R; Otsuki M; Tashima M; Obana Y; Nishino T
    J Antimicrob Chemother; 1990 Dec; 26(6):769-81. PubMed ID: 2127928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
    Lim VK; Halijah MY
    Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies of synergistic interaction between aztreonam and cefoperazone.
    Borowski J; Zaremba M; Feliński J
    Chemioterapia; 1987 Jun; 6(2 Suppl):109-10. PubMed ID: 3151329
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity of BMY-28142, a new cephalosporin.
    Norden CW; Neiderriter K
    Chemotherapy; 1987; 33(1):15-7. PubMed ID: 3103990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
    Greenberg RN; Bollinger MR; Alivisatos MR
    Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of bacterial resistance to the third generation cephalosporins and their clinical use.
    Kolár M; Látal T; Hájek V
    J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressive effect of clindamycin on development of beta-lactam resistance in Enterobacter cloacae ATCC 23355.
    Tateda K; Ishii Y; Matsumoto T; Hirakata Y; Yamaguchi K
    J Antimicrob Chemother; 1994 Aug; 34(2):281-6. PubMed ID: 7814290
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of ceftazidime and other antipseudomonal antibiotics against mucoid strains of pseudomonas aeruginosa.
    Christie CD; Baltimore RS
    West Indian Med J; 1988 Jun; 37(2):87-91. PubMed ID: 3146165
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
    Pechère JC; Vladoianu IR
    J Antimicrob Chemother; 1992 May; 29(5):563-73. PubMed ID: 1624394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.